Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
March 31 2022 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™ today announced it is fortifying its oncology and
hematology research acumen by adding Shaalan Beg, M.D., M.S.C.S. to
its Global Management Team.
Dr. Beg comes to Science 37 from the University of Texas,
Southwestern Medical Center in Dallas, Texas where he served as
Medical Director for the Clinical Research Office at the Simmons
Comprehensive Cancer and held the position of Director
Gastrointestinal (GI) Medical Oncology and Associate Professor of
Hematology and Medical Oncology. Nationally, Dr. Beg is a member of
the American Society of Clinical Oncology (ASCO) and the ECOG-ACRIN
Clinical Research Group and has held various committee positions in
these organizations. He is a graduate of ASCO’s Leadership
Development Program and has been a member of the Pancreatic Cancer
Task Force of the National Cancer Institute (NCI) GI Cancer
Steering Committee.
His medical and research training, combined with in-depth
experience as a clinical trial investigator and background of
clinical trial design and execution, adds comprehensive capacity
and operational prowess to Science 37’s Operating Systems and its
ability to configure more agile and decentralized oncology
studies.
“We are pleased to have Dr. Beg join Science 37,” said Jonathan
Cotliar, M.D., Chief Medical Officer of Science 37. “He brings a
wealth of clinical trial expertise and has been at the forefront of
understanding the benefit of agile and decentralized clinical trial
design for oncology studies from his leadership roles at UT
Southwestern Medical Center, as well as NCI’s National Clinical
Trial Network. His experience builds on our mission of enabling
universal access for patients and providers, anywhere.”
“Science 37’s leadership and drive toward more agile and
decentralized clinical trials is long overdue in cancer research,”
said Shaalan Beg, M.D., M.S.C.S., Vice President, Oncology at
Science 37. “It’s a very transformative moment for the industry and
I’m looking forward to helping remove the barriers patients face
when participating in research. This will further enable access and
help ensure the most appropriate clinical trial is available to the
patients who need them most.” About Science 37Science 37 Holdings,
Inc.’s (Nasdaq: SNCE) mission is to enable universal access to
clinical research—making it easier for patients and providers to
participate from anywhere and helping to accelerate the development
of treatments that impact patient lives. As a pioneer of
decentralized clinical trials, the Science 37 Agile Clinical Trial
Operating System (OS) supports today’s more agile clinical research
designs with its full stack, end-to-end technology platform and
centralized networks of patient communities, telemedicine
investigators, mobile nurses, remote coordinators, provider
communities, and data and devices. Configurable to enable almost
any study type, the Science 37 OS enables up to 15x faster
enrollment, 28% better retention and 3x more diverse patient
population with industry-leading workflow orchestration, evidence
generation and data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES
Margie KoomanScience 37Phone: (984) 377-3737Email:
pr@science37.com
INVESTOR RELATIONS:Caroline
PaulGilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024